LifeStance Health Gr Q2 2024 GAAP EPS $(0.06) Beats $(0.07) Estimate, Sales $312.331M Beat $307.565M Estimate
Portfolio Pulse from Benzinga Newsdesk
LifeStance Health Group (NASDAQ: LFST) reported Q2 2024 GAAP EPS of $(0.06), beating the $(0.07) estimate. Sales were $312.331M, surpassing the $307.565M estimate. This represents a significant improvement in both earnings and sales compared to the same period last year.
August 08, 2024 | 10:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
LifeStance Health Group reported better-than-expected Q2 2024 results with EPS of $(0.06) beating the $(0.07) estimate and sales of $312.331M surpassing the $307.565M estimate. This indicates strong performance and significant improvement over the same period last year.
The better-than-expected earnings and sales figures indicate strong operational performance and financial health, which is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100